AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04003753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR App
Description: Participants will be exposed in three different virtual height scenarios (rural mountain, urban town, cloudy weather). At the beginning of each exposure session participants will be standing on a virtual platform at ground level (level 0). From level 0 they will proceed to further levels according to a predefined exposure scheme based on SUDS ratings (scale 0=no fear to 10=extreme fear). Participants will have to stay at each level until their SUDS are 3 or below for two times consecutively (assessment via gaze selection). In each scenario there will be 15 different height levels available (corresponding to a range of heights between 1-75m). Each exposure session will be terminated by a time limit of 20 minutes (study phase 1) or 30 minutes (study phase 2) irrespective of achieved level.
Study NCT03927638 — intervention group
Intervention type: BEHAVIORAL
Intervention: sit/stand
Description: Subjects will be asked to both sit and stand during a single trial.
Study NCT02600000 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Myocardial scintigraphy
Description: Myocardial scintigraphy with Iodo123-Metaiodobenzylguanidine (MIBG) to assess the Sympathetic myocardial activity
Study NCT02600000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary test
Description: Assessment of maximal functional capacity
Study NCT02600000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVD-Glittre Test
Description: Evaluation of submaximal functional capacity after inspiratory muscle training.
Study NCT02600000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diaphragm ultrasound
Description: Evaluation of thickness and diaphragmatic mobility
Study NCT03777202 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Description: High-flow nasal oxygen will be applied to the patients using Optiflow system through nasal openings during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
Study NCT02721134 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: additional blood tubes
Description: four whole blood tubes 5 ml (2 + EDTA tubes separating gel and dry tubes 2 + separating gel ) will be taken in order to assay more bacterial biomarkers on day 0 , J1, J2, J3 and J5
Study NCT03657030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN424
Description: SAD / MAD
Study NCT03657030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02912208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag/Revolade
Description: Eltrombopag 50 mg once daily has been selected as the starting dose for this study. Thereafter, dependent on platelet response the dose of study medication can be increased by 50 mg every 2 weeks, up to a maximum dose of 300 mg once daily (150 mg in subjects of East Asian ethnicity).
Study NCT02912208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The administration is the same of eltrombopag
Study NCT01896349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPT+ antidepressant drugs
Description: 16 sessions of interpersonal psychotherapy plus antidepressant drugs.
Study NCT01452594 — intervention group
Intervention type: DRUG
Intervention: Diphenylcyclopropenone
Description: Topical administration
Study NCT01452594 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Placebo
Study NCT02079168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXI-109
Study NCT02079168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04108247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone+SHR3162
Description: Participants will receive Abiraterone combined with SHR3162 orally
Study NCT02646449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
Study NCT02646449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
Study NCT02839421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root Planing combined with moxifloxacin
Description: Scaling and Root Planing combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days
Study NCT02839421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing combined with moxifloxacin
Description: Scaling and Root Planing combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days
Study NCT02839421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and Root Planing combined with moxifloxacin
Description: Scaling and Root Planing combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days
Study NCT04529447 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: The patient satisfaction survey consisted of 8 items, including 7 Likert scale questions and 1 multiple choice question.
Study NCT02384694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zumba dance
Description: Twelve weeks, 3 times weekly 1 hour training
Study NCT02794857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP001
Study NCT02794857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00206492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iressa
Description: Iressa
Study NCT00206492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen
Study NCT01524250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: 1250mg of oral prednisone daily for 3 days
Study NCT01524250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: 1000mg IV methylprednisolone daily for 3 days
Study NCT04320550 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: abdominal ultra sound
Description: non invasive tests to exclude pathological causes
Study NCT00140660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 on D1
Study NCT02278419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir 150 mg capsule orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
Study NCT02278419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
Study NCT04624347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to video and movement curves
Description: intervention of caregivers with access to videos and motion curves of the premature infant
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: Antidepressant drugs, clinician´s free choice oriented by guidelines. Monotherapy or combinations are allowed
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: Antidepressant drugs, clinician´s free choice oriented by guidelines. Monotherapy or combinations are allowed
Study NCT04252222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy with VL3
Description: Tracheal Intubation aided by VL3 Videolaryngoscope
Study NCT03757273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FFF with CAD/CAM customized cutting guide
Description: This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton and lower legs. the CT scan will be sent to the modeling company for producing autoclavable 3D models and cutting guides of the mandible and fibula to be used during the workflow as well as a model of the final reconstructed mandible. Surgery will be performed by two surgical teams, one for cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, osteotomy guides secured; cuts then accomplished as planned virtually. fibular flap is harvested and cutting guides secured to replicate osteotomies and reshaping as planned to conform with remaining mandible. fixation and pedicle anastomosis is performed. Finally, the operation completed with soft tissue reconstruction.
Study NCT03757273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FFF without customized cutting guide
Description: This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton. the C.T scan will be sent to the modeling company for planning three-dimensional model of the mandible. autoclavable model will be prepared for mandible to be used during the workflow for plate reshaping and positioning to conform with the remaining mandible.~Surgery will be performed by two surgical teams, one in charge of cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, and resection/ reconstruction then performed in conventional surgical manner with microvascular anastomosis. Finally, the operation will be completed with soft tissue reconstruction.
Study NCT02765217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Description: Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on efficacy.
Study NCT02765217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on
Study NCT02765217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanic Acid
Description: All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.
Study NCT02765217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-Clavulanic Acid
Description: All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.
Study NCT00372762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bumetanide
Description: 0.5mg to 2mg orally once or twice daily
Study NCT03641859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: The virtual reality headset can be used for 45 minutes with the need to pause for 5 minutes if the gesture lasts longer. The VR sequence will be complete when the end of the programmed time is reached to preserve the patient's immersion. The patient will be able to see the final sequence at the end of the gesture in order to get used to the real world again. The programs and their durations will be adjusted to the duration of the gesture concerned. Regarding the pain, anxiety and satisfaction visual analogue scales, they will be performed just after the removal of the VR helmet.~Virtual reality videos are from Healthy Mind® software. The videos are contemplative with three kinds of relaxing landscapes accompanied by a sound universe specifically composed to relax the patient. The patient can choose one of three interactive worlds (an Asian garden, a forest or a mountain).
Study NCT02218320 — intervention group
Intervention type: DRUG
Intervention: Raltegravir
Study NCT02218320 — intervention group
Intervention type: DRUG
Intervention: Dolutegravir
Study NCT02218320 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy with biopsy
Description: This procedure is not standard of care for patients receiving combination antiretroviral therapy (cART), but is necessary to obtain tissue samples.
Study NCT04229420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Rectus sheath block vs Erector spinae plane block
Description: Ultrasound guided Rectus sheath block vs Erector spinae plane block
Study NCT03777202 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low-flow nasal oxygen
Description: Low-flow nasal oxygen will be applied to the patients through nasal openings using conventional nasal cannula during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
Study NCT02290964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ANH
Description: After general anesthesia is applied, blood was taken through the cubital vein and collected into standard blood bags containing CPDA anti-coagulant. The blood obtained is then stored at temperature of 23 - 25 Celsius degree and given back to patients in the operating room after the bleeding stopped and as soon as there are indications of transfusion.
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Study NCT01654042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged interval between PT testing
Description: Patients in the intervention group will be scheduled for prothrombin time testing and dosing of warfarin every 12 weeks instead of every 4 weeks. This has been suggested in the latest edition of the ACCP guidelines as a possibility for very stable patients. In order to change this from a suggestion to a formal recommendation a study powered for clinically important outcomes is needed.
Study NCT01581684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 411034
Description: Medium dose solution for oral administration
Study NCT02331615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuroConn_CE_DC-STIMULATOR
Description: right frontal anodal stimulation
Study NCT02331615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuroConn_CE_DC-STIMULATOR
Description: left frontal anodal stimulation
Study NCT02331615 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: no meaningful stimulation will be given
Study NCT04414839 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Intubation (Two-finger)
Description: In the NGT Digital Intubation group (group B), the second and third fingers were placed in the posterior pharynx and depressed the tongue downwards. The NGT was passed through the nose into the posterior pharynx with the fingers in the pharynx to reach the esophagus. The thumb was placed under the jaw and pushed it forward to pave the way for tube insertion.
Study NCT04414839 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscopy
Description: In the NGT Video Laryngoscopy group (group A), first, the GlideScope blade was inserted under direct visualization via color monitor through the patient's mouth by employing jaw-thrust maneuver to preserve the cervical spine and by raising the tongue to obtain better visualization of the larynx space. Then, NGT was inserted through the selected nostril, advanced through the esophagus under direct vision to meet the measured length, and fixed after confirmation.
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Study NCT03817801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NSE balloon
Description: NSE (Goodman®) predilation + DCB (Sequent® Please) treatment
Study NCT03817801 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NC balloon
Description: NC balloon predilation + DCB (Sequent® Please) treatment
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluvoxamine
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvoxamine
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Study NCT01581684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 411034
Description: High dose solution for oral administration
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Study NCT03926455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhax (investigational typhoid fever candidate vaccine)
Study NCT03926455 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered to the control group on Day 0 and 28
Study NCT03926455 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo is administered to the control group on Day 0 and 28
Study NCT01635062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Subjects will receive calcitriol (up to 0.75 mcg daily) for 3 weeks.
Study NCT01635062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo for 3 weeks.
Study NCT01484418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure in vivo
Description: 5-10 sessions based on an individualized fear hierarchy
Study NCT00560222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: bovine lactoferrin
Description: 1gm of lactoferrin will be given each day
Study NCT01484418 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Psychotherapy
Description: graded activity, relaxation techniques and cognitive interventions
Study NCT00862238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Messaging
Description: 4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, \& C
Study NCT00560222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo [maltodextrin]
Description: placebo that appears identical to lactoferrin will be given daily
Study NCT02373241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Standard dosing
Study NCT02373241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Experimental dosing
Study NCT03798184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-carious cervical lesion restoration
Description: Restoration of non-carious cervical lesions with Prime\&Bond Active in self-etch or selective-etch mode with or without bioglass
Study NCT03798184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-carious cervical lesion restoration
Description: Restoration of non-carious cervical lesions with Prime\&Bond Active in self-etch or selective-etch mode with or without bioglass
Study NCT03926455 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Typhim Vi
Description: A single dose of commercial typhoid fever vaccine Typhim Vi is administered on Day 0, followed by placebo control on Day 28
Study NCT03279653 — intervention group
Intervention type: PROCEDURE
Intervention: SleeveGastrectomy
Description: Preoperative enzyme test before and after sleeve gastrectomy. Sleeve Gastrectomy will be performed. Preoperative (in one month) and Postoperative (after 3 months) pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
Study NCT03809221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin acetate
Description: Achieve pituitary down regulation with triptorelin acetate and start controlled ovarian stimulation after complete pituitary down regulation
Study NCT03809221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin acetate
Description: Achieve pituitary down regulation with triptorelin acetate and start controlled ovarian stimulation after complete pituitary down regulation
Study NCT02094053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2020-Donepezil hydrochloride
Description: 3 mg of E2020 (oral) once daily, for 24 weeks
Study NCT01317992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast
Description: Ibudilast 4 x 10 mg capsules, orally, twice daily for 8 weeks.
Study NCT02094053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2020-Donepezil hydrochloride
Description: 5 mg of E2020 (oral) once daily, for 24 weeks
Study NCT01317992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 capsules, orally, twice daily for 8 weeks.
Study NCT01098747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel Ibuprofen
Description: Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
Study NCT01098747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ibuprofen
Description: Single-dose of standard ibuprofen (400mg)
Study NCT01098747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single-dose of placebo